RxDoctor Payments Data

Joel Ferguson

Family · Anderson, INNPI 1932565561

Payments from drug & device makers

$1,402in general payments, 2019–2025

Across 78 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$350
  • Novo Nordisk$199
  • Medtronic$162
  • Lilly USA, LLC$150
  • Xeris Pharmaceuticals, Inc.$120
  • Sanofi-aventis U.S. LLC$113
  • plus $308 from 8 others

What the payments were for

  • Food & beverage$1,38299%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,402 in reported general payments places this provider in the 70th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$8,087
Medicare patients
34
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$107,893
Tresiba Flextouch U-200Insulin Degludec20$55,805
JardianceEmpagliflozin51$52,378
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog36$52,076
Tresiba Flextouch U-100Insulin Degludec64$40,772
TrulicityDulaglutide31$40,624
MounjaroTirzepatide15$26,420
Janumet XrSitagliptin Phos/Metformin Hcl11$14,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$14,056
FarxigaDapagliflozin Propanediol14$11,423
TradjentaLinagliptin13$10,318
Humalog Kwikpen U-100Insulin Lispro22$8,327
Soliqua 100-33Insulin Glargine/Lixisenatide15$5,696
HumalogInsulin Lispro24$4,904
NovologInsulin Aspart31$4,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$199$112,348124 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$150$71,94870 claims
MerckJanumet Xr$16$14,31011 claims
AstraZenecaFarxiga$13$11,42314 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$113$5,69615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,392 family providers in Indiana.

Other family in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →